Applied DNA Sciences (APDN)
(Delayed Data from NSDQ)
$1.96 USD
-0.55 (-21.91%)
Updated May 20, 2024 03:59 PM ET
2-Buy of 5 2
C Value B Growth A Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
APDN 1.96 -0.55(-21.91%)
Will APDN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for APDN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for APDN
Applied DNA Sciences (APDN) Reports Q2 Loss, Tops Revenue Estimates
Clear Secure (YOU) Q1 Earnings and Revenues Top Estimates
APDN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Rockwell Automation (ROK) Q2 Earnings and Revenues Surpass Estimates
Allegion (ALLE) Q1 Earnings Surpass Estimates
Is Applied DNA Sciences (APDN) Outperforming Other Industrial Products Stocks This Year?
Other News for APDN
Why Alcon Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
12 Health Care Stocks Moving In Monday's Intraday Session
Applied DNA Sciences announces presentation on use of Linea DNA
Institute of Hematology and Blood Transfusion (Prague) to Present on Successful Use of Applied DNA's Linea DNATM for the Non-Viral Manufacture of CAR T-Cell Therapy for Refractory AML
LIDR, ELDN and IVP among pre-market losers